{"id":24757,"date":"2025-09-16T14:35:35","date_gmt":"2025-09-16T12:35:35","guid":{"rendered":"https:\/\/lombardialifesciences.it\/?p=24757"},"modified":"2025-09-16T14:41:37","modified_gmt":"2025-09-16T12:41:37","slug":"eu4health-2025-al-via-al-nuovo-bando-hera","status":"publish","type":"post","link":"https:\/\/lombardialifesciences.it\/en\/eu4health-2025-al-via-al-nuovo-bando-hera\/","title":{"rendered":"EU4Health 2025: al via il nuovo bando HERA"},"content":{"rendered":"<p>L&#8217;Agenzia esecutiva europea per la salute e il digitale (<strong>HaDEA<\/strong>) ha pubblicato\u00a0<strong>un nuovo bando<\/strong>\u00a0nel settore della diagnostica, dello sviluppo di dispositivi medici e della preparazione alla crisi sanitarie, nell&#8217;ambito dello\u00a0<em>strand<\/em>\u00a0<em>Crisis Preparedeness<\/em>\u00a0del\u00a0<a href=\"https:\/\/health.ec.europa.eu\/publications\/2025-eu4health-work-programme_en\" target=\"_blank\" rel=\"noopener\"><strong>programma di lavoro 2025<\/strong><\/a>\u00a0di\u00a0<strong>EU4Health<\/strong>, recentemente pubblicato.<\/p>\n<p><strong>EU4Health\u00a0<\/strong>\u00e8 il quarto programma dell&#8217;Unione europea dedicato alla salute in vigore per il periodo 2021-2027. Il programma punta a integrare le\u00a0<strong>politiche degli Stati membri<\/strong>\u00a0al fine di\u00a0<strong>migliorare la salute umana<\/strong>\u00a0garantendone la protezione in tutte le politiche e attivit\u00e0 dell\u2019Unione, in linea con l\u2019<strong>approccio One Health<\/strong>.<\/p>\n<p>In particolare, il bando \u00e8 articolato in\u00a0<strong>4 topic<\/strong>:<\/p>\n<ul>\n<li><strong>EU4H-2025-HERA-PJ-1-a<\/strong>\u00a0&#8211; Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) &#8211; Medicinal products &#8211;\u00a0<strong>18 milioni di euro<\/strong><\/li>\n<li><strong>EU4H-2025-HERA-PJ-1-b<\/strong>\u00a0&#8211; Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) &#8211; Reusable respiratory personal protective equipment (PPE) and protection suits &#8211;\u00a0<strong>1 milione di euro<\/strong><\/li>\n<li><strong>EU4H-2025-HERA-PJ-1-c<\/strong>\u00a0&#8211; Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) &#8211; Detection and diagnosis &#8211;\u00a0<strong>1 milione di euro<\/strong><\/li>\n<li><strong>EU4H-2025-HERA-PJ-2<\/strong>\u00a0&#8211; Call for proposals for the development of new diagnostic tests for vector-borne diseases (HERA) &#8211;\u00a0<strong>10 milioni di euro<\/strong><\/li>\n<\/ul>\n<p>Per essere ammissibili al finanziamento, i richiedenti devono essere persone giuridiche (<strong>enti pubblici o privati<\/strong>) ed essere stabiliti in uno dei paesi ammissibili, cio\u00e8:\u00a0<strong>Stati membri dell&#8217;UE<\/strong>\u00a0(compresi i Paesi e Territori d&#8217;Oltremare),\u00a0<strong>paesi del SEE<\/strong>\u00a0elencati e\u00a0<strong>paesi associati<\/strong>\u00a0al programma EU4Health\u00a0indicati in questo\u00a0<a href=\"https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/docs\/2021-2027\/eu4h\/guidance\/list-3rd-country-participation_eu4h_en.pdf\" target=\"_blank\" rel=\"noopener\" data-once=\"first.linkTarget\">documento<\/a>.<\/p>\n<p>Il budget disponibile totale \u00e8 di\u00a0<b>30 milioni<\/b>\u00a0<strong>euro<\/strong>.<\/p>\n<p>La scadenza per presentare le candidature \u00e8 per tutti i bandi il\u00a0<b>4 dicembre 2025<\/b>.<\/p>\n<p><strong><a href=\"https:\/\/health.ec.europa.eu\/publications\/2025-eu4health-work-programme_en\" target=\"_blank\" rel=\"noopener\">Clicca qui<\/a><\/strong> per ulteriori informazioni.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;Agenzia esecutiva europea per la salute e il digitale (HaDEA) ha pubblicato\u00a0un nuovo bando?&#8230;<\/p>\n","protected":false},"author":4,"featured_media":12285,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[44],"tags":[76,377],"class_list":["post-24757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-bandi","tag-eu4health"],"acf":[],"_links":{"self":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/24757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/comments?post=24757"}],"version-history":[{"count":4,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/24757\/revisions"}],"predecessor-version":[{"id":24761,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/24757\/revisions\/24761"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media\/12285"}],"wp:attachment":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media?parent=24757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/categories?post=24757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/tags?post=24757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}